Company: RGNT
Filing Date: 2025-03-11
Form Type: F-1
Source: 0001213900-25-022350
Chunk: 2

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-03-11
Form: F-1
Chunk 2
---
 soliciting an offer to buy these securities in any state where the offer or sale is not permitted.

909,090 Ordinary Shares

Regentis Biomaterials Ltd.

This is a firm commitment initial public
offering of ordinary shares, par value NIS 0.01 per share, or Ordinary Shares, of Regentis Biomaterials Ltd. The anticipated initial
public offering price will be between $10.00 and $12.00 per Ordinary Share. The number of Ordinary Shares offered hereby is
based upon an assumed initial offering price of $11.00 per Ordinary Share, the midpoint of such estimated price range. For a discussion
of the factors to be considered in determining the initial public offering price of the Ordinary Shares, see “Underwriting”.

Prior to this offering, there has been no public
market for our Ordinary Shares. We have applied to list our Ordinary Shares on the Nasdaq Capital Market under the symbol “RGNT”.
It is a condition to the closing of this offering that our Ordinary Shares shall have been approved for listing on the Nasdaq Capital
Market. No assurance can be given that our application will be approved or that a trading market will develop.

We are both an emerging growth company, as defined
in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and a “foreign private issuer,” as defined under the
U.S. federal securities laws and are subject to reduced public company reporting requirements. See “Prospectus Summary—Implications
of Being an Emerging Growth Company and a Foreign Private Issuer” for additional information.

Investing in our securities involves a high degree of risk. See “Risk Factors” beginning on page 14.

None of the Securities and Exchange Commission, or the SEC, the Israeli Securities Authority, or any state or other foreign securities commission has approved nor disapproved these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

|                                            |     | Per Share |     | Total |
|:-------------------------------------------|:----|:----------|:----|:------|
| Initial public offering price              |     | $         |     | $     |
| Underwriting discounts and commissions (1) |     | $         |     | $     |
| Proceeds to us (before expenses)           |     | $         |     | $     |

| (1) | Underwriting                                                                                     
 discounts and commissions do not include a non-accountable expense allowance equal